Perioperative chemotherapy with the FLOT protocol showed longer overall survival in patients with advanced esophageal adenocarcinoma compared to the CROSS regimen in a randomized phase 3 trial. The FLOT arm had a median overall survival almost 2.5 years longer than the CROSS arm. The study included 438 adults with esophageal adenocarcinoma and assessed the impact of each treatment regimen on overall survival. The FLOT group had lower mortality rates following surgery and a higher overall survival rate. Researchers plan to investigate whether surgery is necessary for patients with esophageal adenocarcinoma who achieve a complete response to chemotherapy.
Source link
Chemotherapy regimen improves survival in advanced esophageal cancer
